Last updated on February 2018

Neoadjuvant Pembrolizumab in Combination With Gemcitabine Therapy in Cis-eligible/Ineligible UC Subjects


Brief description of study

This is a pre-surgical study involving subjects with muscle invasive bladder cancer, or urothelial cancer, who are candidates for neoadjuvant therapy. It is is a two-part trial with a one-arm phase Ib portion followed by a two-arm phase II portion. The study treatment is stratified into two cohorts based on cisplatin eligibility.

Detailed Study Description

OUTLINE: This is a multi-center study.

INVESTIGATIONAL TREATMENT:

Phase Ib Dose-Finding Cohort I Cisplatin-Eligible:

Phase Ib is a 3+3 design for the cisplatin-eligible group only. Cisplatin-eligible subjects receive: gemcitabine 1000mg/m2 IV D1 and D8 every 21 days repeated for 4 cycles; cisplatin 70mg/m2 IV D1 and D8 every 21 days, repeated for 4 cycles. (Subjects with Ccr of 50-59 mL/min must follow split dosing of cisplatin over two days). Pembrolizumab will be given every 3 weeks for 5 doses, with a starting dose of 200 mg. NOTE: the last dose of pembrolizumab falls on what would be D8 of a 5th 'chemo' cycle, however gemcitabine/cisplatin is NOT GIVEN.

Phase II Arm A: Cohort I Cisplatin-Eligible:

Cisplatin-eligible subjects receive: gemcitabine 1000mg/m2 IV D1 and D8 every 21 days repeated for 4 cycles; cisplatin 70mg/m2 IV D1 and D8 every 21 days, repeated for 4 cycles. (Subjects with Ccr of 50-59 mL/min must follow split dosing of cisplatin over two days). Pembrolizumab at recommended phase II dose (RP2D) is given every 3 weeks for 5 doses starting with C1D8. NOTE: the last dose of pembrolizumab falls on what would be day 8 of a 5th 'chemo' cycle, however gemcitabine/cisplatin is NOT GIVEN. Cohort I treatment with gemcitabine and cisplatin will continue for a maximum of 4 cycles (cycle = 21days).

Phase II Arm B: Cohort II:

Cisplatin-ineligible subjects receive gemcitabine 1000mg/m2 IV D1, D8 and D15 every 28 days, repeated for 3 cycles. Pembrolizumab at RP2D is given every 3 weeks for 5 doses starting with C1D8. NOTE: due to the timing of gemcitabine cycles every 4 weeks, and every three week dosing of pembrolizumab, there are two doses of pembrolizumab given during cycle 2: D1 and D22. Additionally, the last dose of pembrolizumab falls on what would be D8 of a 4th 'chemo' cycle; however gemcitabine is NOT GIVEN. Cohort II treatment with gemcitabine will continue for a maximum of 3 cycles (cycle = 28 days)

Subjects will then have surgery to remove their primary tumor within 2-7 weeks after their last dose of neoadjuvant therapy.

Eastern Cooperative Oncology Group (ECOC) performance status: 0-1 for cisplatin-eligible subjects; 0-2 for cisplatin-ineligible subjects.

Demonstrate adequate organ function as defined by the following laboratory values at study entry. All screening labs should be performed within 28 days of C1D1.

Hematopoetic
  • Absolute neutrophil count (ANC) 1,500 /mcL
  • Absolute lymphocyte count 350 mcL
  • Platelets 100,000 / mcL
  • Hemoglobin 9 g/dL or 5.6 mmol/L
Renal
  • Measured or calculated creatinine clearance 30 mL/min
Hepatic
  • Serum total bilirubin 1.25 X ULN OR 2.5 x ULN for subjects with Gilbert's disease
  • Aspartate aminotransferase (AST, SGOT) and alanine aminotransferase (ALT, SGPT) 2 X ULN
Coagulation
  • International Normalized Ratio (INR) or Prothrombin Time (PT) 1.5 X ULN unless subject is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants
  • Activated Partial Thromboplastin Time (aPTT) 1.5 X ULN unless subject is receiving anticoagulant therapy and as long as PT or PTT is within therapeutic range of intended use of anticoagulants

Clinical Study Identifier: NCT02365766

Contact Investigators or Research Sites near you

Start Over

Costantine Albany, M.D.

Indiana University Melvin and Bren Simon Cancer Center
Indianapolis, IN United States
  Connect »

Joel Picus, M.D.

Washington University: Siteman Cancer Center
Saint Louis, MO United States
  Connect »

Christopher Hoimes, D.O.

University Hospitals Seidman Cancer Center
Cleveland, OH United States
  Connect »

Jean Hoffman-Censits, M.D.

Thomas Jefferson University: Kimmel Cancer Center
Philadelphia, PA United States
  Connect »

Mark Fleming, M.D.

Virginia Oncology Associates
Norfolk, VA United States
  Connect »

Radhika Walling, MD

Community Regional Cancer Care
Indianapolis, IN United States
  Connect »

Niraj Gupta, MD

St. Vincent Hospital
Indianapolis, IN United States
  Connect »